Dr. Mehra is a Professor of Medicine at Harvard University and serves as Medical Director of the Heart and Vascular Center as well as Executive Director of the Center for Advanced Heart Disease, Brigham and Women’s Hospital in Boston, MA (USA). Additionally, he is Editor-in-Chief, The Journal of Heart and Lung Transplantation. Dr. Mehra is Past-President of the International Society of Heart and Lung Transplantation (ISHLT) and President of the Heart Failure Society of America (HFSA). Dr. Mehra has authored and published over 400 papers focusing on all aspects of advanced heart failure, mechanical circulatory support and transplantation. One important focus area is in developing international guidelines for care of advanced heart failure and implementation science in heart failure. He is leading pivotal clinical trials in the field of Mechanical Circulatory Support, with novel left ventricular assist systems. In 2012, Dr. Mehra was awarded an Honorary Masters from Harvard University and is currently pursuing a Masters at the London School of Economics on Health Economics, Outcomes and Management.

Deepak L. Bhatt MD, MPH, FACC, FAHA, FSCAI, FESC, is Executive Director of Interventional Cardiovascular Programs at Brigham and Women’s Hospital Heart & Vascular Center and Professor of Medicine at Harvard Medical School. He is also a Senior Physician at Brigham and Women’s Hospital and a Senior Investigator in the TIMI Study Group. After graduating as valedictorian from the Boston Latin School, Dr. Bhatt obtained his undergraduate science degree as a National Merit Scholar at the Massachusetts Institute of Technology while also serving as a research associate at Harvard Medical School. He received his medical doctorate from Cornell University. He completed a Master in Public Health with a concentration in clinical effectiveness at Harvard University. His internship and residency in internal medicine were performed at the Hospital of the University of Pennsylvania, and his cardiovascular training was at Cleveland Clinic. He also completed fellowships in interventional cardiology and cerebral and peripheral vascular intervention as well as serving as Chief Interventional Fellow at Cleveland Clinic, where he spent several years as an interventional cardiologist and an Associate Professor of Medicine. He served for many years as Director of the Interventional Cardiology Fellowship and as Associate Director of the Cardiovascular Medicine Fellowship. He also served as Associate Director of the Cleveland Clinic Cardiovascular Coordinating Center. He was then recruited to be the Chief of Cardiology at VA Boston Healthcare System and served in that role for several years. Dr. Bhatt has been listed in Best Doctors in America from 2005 to 2016. He was selected by Brigham and Women’s Hospital as the 2014 Eugene Braunwald Scholar. Dr. Bhatt’s research interests include acute coronary syndromes, preventive cardiology, and advanced techniques in cardiac, cerebral, and peripheral intervention. He has authored or co-authored over 750 publications and is listed as a Thomson Reuters Highly Cited Researcher. He is the Editor of Cardiovascular Intervention: A Companion to Braunwald’s Heart Disease and Atherothrombosis in Clinical Practice published by Oxford University Press. He was the international PI for the CHARISMA and CRESCENDO trials and co-PI of the three CHAMPION trials. He served as chair of COGENT and helped lead STAMPEDE. He serves as co-chair of the REACH registry and chairs REDUCE-IT. He is co-PI of SAVOR-TIMI 53, SYMPLICITY HTN-3, and THEMIS. In 2014, he was listed in the AHA/ASA top ten advances in heart disease and stroke research (for STAMPEDE and SYMPLICITY HTN-3). He is the Chair of the AHA-GWTG Quality Oversight Committee. He is a Trustee of the ACC. He is Senior Associate Editor for News and Clinical Trials for ACC.org. He is the Editor of the peer-reviewed Journal of Invasive Cardiology, Chief Medical Editor of Cardiology Today’s Intervention for healthcare professionals, and Editor-in-Chief of the Harvard Heart Letter for patients.

Marc P. Bonaca, MD, MPH is a specialist in Vascular Medicine, an Associate Physician in Cardiovascular Medicine at Brigham and Women's Hospital, an Assistant Professor of Medicine at Harvard Medical School and an investigator at the TIMI Study Group. Dr. Bonaca earned his medical degree (M.D.) from University of Connecticut School of Medicine and a Master of Public Health (M.P.H.) from the Harvard School of Public Health. He completed his internal medicine residency, cardiovascular medicine fellowship and vascular medicine fellowship at Brigham and Women's Hospital. He is board certified in internal medicine and cardiology. Dr. Bonaca's research interests include characterization and prediction of cardiovascular risk in patients with atherosclerotic vascular disease as well as investigation of therapies to reduce that risk. Specific disease states of interest include peripheral artery disease, stable coronary artery disease, and aortic disease. He is an active investigator in clinical trials investigating novel therapies including antithrombotic agents for the reduction of cardiovascular risk in patients with symptomatic peripheral artery disease and stable coronary disease. In addition, he is actively involved in the evaluation of established and novel biomarkers as well as clinical characteristics for risk prediction in specific patient populations. In addition to scientific investigation and clinical trial work, Dr. Bonaca leads the TIMI Safety Desk which includes 20 staff members and which is responsible for the monitoring and processing of safety data for multiple large international clinical trials. In addition to his scientific, clinical trial, and safety responsibilities, Dr. Bonaca is an active member of the clinical staff at Brigham and Women's hospital and attends on the inpatient cardiology and cardiology/vascular medicine consult services. He is the Medical Director of the Acute Aortic Syndrome Program at Brigham and Women’s Hospital and maintains a regular clinic seeing complex vascular patients.

Dr. Matthew Menard is an associate vascular surgeon at the Brigham and Women’s Hospital in Boston, Massachussetts. Dr. Menard graduated summa cum laude from Middlebury College and earned his medical degree from Harvard Medical School. He received his general surgery training at the Massachusetts General Hospital and vascular surgery fellowship training at the Brigham and Women’s Hospital. He is Co-Director of Endovascular Surgery and the Vascular and Endovascular Surgery Fellowship Program Director at the Brigham and Women's Hospital. Dr. Menard is a National Principal Investigator of the BEST-CLI Trial, an NIH-sponsored study investigating the comparative-effectiveness of open surgery versus endovascular therapy for critical limb ischemia (CLI), the only such study to be undertaken in North America. The trial is a randomized, controlled, superiority trial examining treatment efficacy, functional outcomes and cost of endovascular and open surgical revascularization in patients with CLI. The trial will enroll 2100 patients from 150 clinical sites in the United States and Canada who are candidates for both treatment modalities. Dr. Menard has a busy surgical practice equally split between open vascular and endovacular surgery.

Dr. Weinberg is Assistant Professor of Medicine in Harvard Medical School. He is the Medical Director of VASCORE, the Massachusetts General Hospital Ultrasound Core Lab and co-Medical Director of the Massachusetts General Hospital Anticoagulation Management Services. He is the Director of the Vascular Medicine Fellowship at Massachusetts General Hospital. His is founder and editor in chief of Angiologist.com and can be followed @Angiologist.

Dr. Guzman is an Associate Professor of Surgery, Harvard Medical School, and Director of Vascular Surgery Research at the Beth Israel Deaconess Medical Center. He also heads the Vascular Clinic at the Joslin Diabetes Center. His research focuses on the effects of diabetes and arterial calcification on long term outcomes in patients with peripheral artery disease.